Impact of epidermal growth factor receptor and transforming growth factor-α on hepatitis C virus-induced hepatocarcinogenesis

Bibliographic Information
Authors: Badawy A.A.-G.; El-Hindawi A.; Hammam O.; Moussa M.; Gabal S.; Said N.
Journal: APMIS
Publisher: Blackwell Munksgaard
Publication Date: 17 August 2015
Volume / Issue: Volume 123 / Issue 10
Pages: 823–831
ISSN: 9034641
DOI: 10.1111/apm.12431
Scopus: View on Scopus
PubMed: 26279457
Document Type: Review
Authors and Affiliations
Badawy A.A.-G., Department of Pathology, Theodor Bilharz Research Institute, Imbaba, Egypt; El-Hindawi A., Faculty of Medicine, Cairo University, Giza, Egypt; Hammam O., Department of Pathology, Theodor Bilharz Research Institute, Imbaba, Egypt; Moussa M., Department of Pathology, Theodor Bilharz Research Institute, Imbaba, Egypt; Gabal S., Faculty of Medicine, Cairo University, Giza, Egypt; Said N., Department of Pathology, Theodor Bilharz Research Institute, Imbaba, Egypt
Abstract
Epidermal growth factor receptor system plays a central hepato-protective and pro-regenerative role in liver. Transforming growth factor-α (TGF-α) is an important autocrine growth regulator of hepatocytes that plays a role in development of hepatocellular carcinoma (HCC) among patients with chronic hepatitis C (CHC). This study was done on 40 core liver biopsies from patients with CHC, 20 liver specimens from HCC cases on top of CHC as well as five normal controls. All were immunohistochemically stained with epidermal growth factor receptor (EGFR) and TGF-α antibodies. Some selected HCC cases were submitted for FISH technique to detect EGFR gene alteration. By immunohistochemistry EGFR and TGF-α were overexpressed in HCC and cirrhotic cases compared to CHC cases without cirrhosis. Also, their expression was stronger in CHC cases with higher grades of activity and stages of fibrosis compared to lower ones. FISH positive results for EGFR were detected in 33.3% of the examined HCC cases. EGFR and TGF-α can be used as predictive markers for activity, fibrosis, and carcinogenesis in CHC patients. Overexpression of EGFR in HCC patients can be promising in selecting those who can get benefit from anti-EGFR target therapy. © 2015 APMIS Published by John Wiley & Sons Ltd.
Keywords
Chronic hepatitis C; Epidermal growth factor receptor; Fluorescence in situ hybridization; Immunohistochemistry; Transforming growth factor-α; Adult; Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; In Situ Hybridization, Fluorescence; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Receptor, Epidermal Growth Factor; Transforming Growth Factor alpha; EGFR protein, human; tumor marker; clinical article; clinical assessment; comparative study; controlled study; gene overexpression; Hepatitis C virus; histopathology; human; human tissue; immunoreactivity; liver biopsy; liver carcinogenesis; liver cell carcinoma; liver fibrosis; liver protection; molecularly targeted therapy; mutation; priority journal; protein expression; Review; genetics; liver cell; liver tumor; metabolism; pathogenicity; virology
Citation Information
Scopus Citations: 25
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
